SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096626
Filing Date
2024-08-14
Accepted
2024-08-14 06:06:54
Documents
69
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q elym-20240630.htm   iXBRL 10-Q 2048940
2 EX-31.1 elym-ex31_1.htm EX-31.1 16192
3 EX-31.2 elym-ex31_2.htm EX-31.2 15677
4 EX-32.1 elym-ex32_1.htm EX-32.1 9622
5 EX-32.2 elym-ex32_2.htm EX-32.2 9108
  Complete submission text file 0000950170-24-096626.txt   8002658

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elym-20240630.xsd EX-101.SCH 1255807
72 EXTRACTED XBRL INSTANCE DOCUMENT elym-20240630_htm.xml XML 1189013
Mailing Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808
Business Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808 877-354-3689
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

IRS No.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40708 | Film No.: 241203935
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)